Review of SURPASS-ET Trial Evaluating Ropeginterferon Alfa-2b-njft for Essential Thrombocythemia (ET) Published in Future Oncology

PharmaEssentia Appoints Dr. Lih-Ling Lin as Chief Scientific Officer

PharmaEssentia Honored at the National Organization of Rare Disorders (NORD(R)) 2022 Rare Impact Awards for the Introduction of BESREMi(R) (ropeginterferon alfa-2b) for Polycythemia Vera

New Data on Ropeginterferon Alfa-2b to be Featured at EHA2022

PharmaEssentia Announces Appointment of Meredith Manning to President of the Americas

PharmaEssentia Japan Files Marketing Authorization Application for Ropeginterferon Alfa-2b For the Treatment of Polycythemia Vera

NCCN Clinical Practice Guidelines in Oncology Update Recommends BESREMi(R) (ropeginterferon alfa-2b-njft) for the Treatment of Polycythemia Vera

PharmaEssentia Expands U.S. Leadership with Anjana Pursnani, Head of People, and Jason Mitch, Head of Market Access

PharmaEssentia’s BESREMi (Ropeginterferon alfa-2b-njft) Now Available For the Treatment of People with PV in the United States

U.S. FDA Approves BESREMi(R) (ropeginterferon alfa-2b-njft) As the Only Interferon for Adults with Polycythemia Vera